Running head: Mechanisms of resistance to PARP inhibitors/platinum in metastatic breast cancer Keywords: BRCA1, BRCA2, breast cancer, PARP inhibitor, platinum Key message: We analyzed mechanisms of resistance to PARP inhibitor or platinum chemotherapy in 8 patients with BRCA1/2-mutant metastatic breast cancer. Four patients acquired resistance by genomic reversion to a functional BRCA1/2 protein; two patients acquired resistance by upregulating DNA end resection. RAD51 foci by immunohistochemistry correlated with clinical response to PARP inhibitor/platinum.
Introduction
Approximately 5% of breast cancer patients carry germline mutations in BRCA1 or BRCA2, 1 tumor suppressor genes that function in the repair of DNA double stranded breaks by homologous recombination (HR). [2] [3] [4] Multiple lines of evidence from in vitro experiments to large-scale randomized clinical trials have demonstrated that BRCA1/2-deficient cancers are particularly sensitive to two classes of DNA-damaging therapies: platinum chemotherapy and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. 1, 5, 6 Platinum agents are increasingly widely used in patients with metastatic breast cancer and germline BRCA1/2 mutations, and two PARP inhibitors (PARPi; olaparib and talazoparib) obtained United States Food and Drug Administration (FDA) approval for this indication in 2018. 7 As the clinical use of these agents expands, it is increasingly important to understand how resistance occurs and to develop biomarkers predictive of response.
Previously described mechanisms of resistance to PARPi or platinum chemotherapy fall into two main categories: alteration of a protein in the HR pathway (including acquired reexpression of functional BRCA protein, known as reversion), [8] [9] [10] and altered expression of a protein in the replication fork protection pathway. 11, 12 Loss of drug efficacy related to overexpression of drug efflux pumps or desmoplastic stromal reaction in tumor tissue has also been reported. 10 Though BRCA1 or BRCA2 reversions have been described in many clinical cohorts, non-reversion mechanisms of resistance are almost exclusively described in in vitro models, and there is great need to explore their relevance in clinical specimens. Furthermore, much of the clinical work to date has been in ovarian cancer and prostate cancer, 10,13-15 with fewer investigations of PARPi or platinum resistance in breast cancer patients. 16, 17 The goal of this study was to use tumor sequencing to identify both reversion and nonreversion mechanisms of acquired resistance to PARPi or platinum chemotherapy in patients with BRCA1/2-deficient metastatic breast cancer. Sequencing of the whole exome and the whole transcriptome was performed in paired tumor specimens before and after acquired resistance to PARPi or platinum. Presence of RAD51 foci (a marker of intact HR) was also measured to assess the functional impact of alterations identified in sequencing results. Our findings suggest two novel non-reversion mechanisms of resistance, and support RAD51 focus formation as a clinically useful biomarker of resistance to PARPi and platinum chemotherapy.
Methods
Further details can be found in Supplemental Methods.
Patient cohort and biopsies
Prior to any study procedures, all patients provided written informed consent for research biopsies and sequencing of tumor and normal DNA, as approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (DF/HCC Protocol 05-246). We identified all patients enrolled on this sequencing study who had germline or somatic deleterious BRCA1 or BRCA2 alteration and a tissue biopsy performed following acquired resistance to PARPi or platinum therapy between July 2015 to July 2017. Acquired resistance was defined as disease progression following either complete response, partial response, or stable disease for a period of >3 months, followed by disease progression on therapy. Patient/tumor characteristics and breast cancer treatment history, including response to each treatment received assessed by a breast medical oncologist, were extracted from the medical record.
Tumor and blood sequencing DNA extraction and construction of libraries for massively parallel sequencing were performed as previously described. 18 Cell-free DNA was isolated and circulating tumor DNA was sequenced using the ichorCNA method, as previously described. 19 Analysis pipeline details follow in Supplemental Methods.
Identification of reversions in BRCA1 and BRCA2
Short frame-restoring indels of length < 100bp were identified using the 2-out-of-3 voting scheme described in the Supplemental Methods regarding somatic alterations. Longer deletions of length >= 100bp were identified using SvABA, and the resulting VCF was annotated using svaba-annotate.R and AnnotSV version 1.2. 20 Long deletions identified in BRCA1 and BRCA2 were checked for validity and impact to the reading frame via manual inspection of the raw reads (*.alignments.txt.gz) aligned to contigs assembled by SvABA.
Immunohistochemical staining
For RAD51 staining, serial sections of FFPE tumor biopsies were stained as previously described 21 using antibodies to RAD51 and Geminin independently. A sample was classified as HR proficient if more than three RAD51 foci were present in a minimum of one cell in three 40X
fields. If RAD51 foci were absent, the sample was classified as HR deficient if greater than 3% of the cells were Geminin positive. If there were no RAD51 foci and less than 3% of the cells were Geminin positive, the proliferation rate of the tumor was classified as low and HR status could not be determined. FFPE sections of a cell line block containing irradiated and unirradiated HR-proficient (HCC1569) and HR-deficient (MDA-MB-436) breast cancer cell lines were used as positive and negative controls. 21 For phosphorylated replication protein A (phospho-RPA) staining, FFPE tumor sections were stained using the standardized immunohistochemical protocol for phospho RPA32 (S4/S8) antibody A300-245A (Bentyl Laboratories). Stained slides were scanned and image analysis was performed on the Aperio platform (Leica Biosystems).
Results

Patient and tumor characteristics
Eight patients with metastatic breast cancer, germline and/or somatic inactivating mutation in BRCA1 or BRCA2, and acquired resistance to any PARPi or platinum chemotherapy were identified (Table 1) . Seven patients were germline mutation carriers and the eighth had a somatic mutation only. The majority of patients had hormone receptor-positive (HR+) tumors due to the fact that the initial focus of the umbrella collection protocol was on HR+ breast cancer. Four of eight patients had acquired resistance to PARPi, and four had acquired resistance to platinum chemotherapy.
Reversions identified in BRCA1 and BRCA2 following exposure to platinum chemotherapy or
PARPi
Four of eight patients demonstrated definite or putative reversion to a functional BRCA1
or BRCA2 open reading frame following acquired resistance to PARPi or platinum chemotherapy. Details of reversion events for all four patients are shown in Figure 1 . The identified reversions suggested restoration of intact HR through reconstitution of functional BRCA1/2 protein as a likely mechanism of resistance to PARPi/platinum chemotherapy in these four patients. Consistent with this, in all four patients the pre-resistance tumors had no RAD51 foci (indicative of defective HR) while the post-resistance tumors demonstrated the acquisition of RAD51 foci (indicative of restoration of HR) (Figure 1A-D) . Table S1 shows the exact genomic coordinates, allelic fraction, and cancer cell fraction for each reversion event. We categorized reversion events as definite (patients 318, 339, and 349) if acquired restoration of BRCA1 or BRCA2 open reading frame could be concluded directly from gene sequence for at least one genomic event, and as putative (patient 510) if open reading frame sequence could not be directly concluded but genomic events nearby to the original inactivating event were newly acquired following resistance to DNA-damaging therapy and accompanied by acquisition of RAD51 foci post-resistance.
In a subset of patients, circulating tumor DNA (ctDNA) was available for sequencing in addition to tumor in a subset of patients. Table S2 shows the number of circulating tumor DNA (ctDNA) specimens that successfully underwent WES from blood in each patient (median 2, range 0-7); 7 patients had successful sequencing of at least one ctDNA specimen (including all 4 patients with reversion events). All ctDNA specimens were drawn close in time or subsequent to post-resistance tumor sampling. In the 4 patients with reversion events, there were 10 total reversion events identified. Six events were found in blood only, 3 were found in tumor only, and 1 was found in blood and tumor, confirmed by manual review of unfiltered sequencing results from both tumor and blood for all events. Of note, two patients had reversions identified only in ctDNA; in both cases, ctDNA was sampled more than tumor.
Genomic analysis of acquired resistance pathways identifies TP53BP1 loss and MRE11A amplification in two patients with BRCA1 germline mutation
We compared tumor whole exome sequencing before and after acquired resistance to PARPi or platinum chemotherapy to identify potential non-reversion mechanisms of resistance to therapy. We focused our initial analysis on single nucleotide variants (SNVs) and copy number variants (CNVs) in 20 genes from pathways previously linked to PARPi/platinum response or resistance in preclinical models and/or clinical specimens. [9] [10] [11] [12] 16, [22] [23] [24] [25] [26] [27] [28] [29] [30] Genomic alterations involving these 20 genes in pre-resistance versus post-resistance tumor specimens from each patient are shown in Figure 2 .
In two patients, we identified acquired genomic alterations anticipated to lead to restoration of HR through increased DNA end resection. Patient 292, with a pathogenic germline mutation in BRCA1 and no identified reversion in BRCA1 after carboplatin treatment ( Figure   3A ), acquired bi-allelic inactivation in TP53BP1 resulting from an antisense fusion between TP53BP1 and GALNT2 plus loss of heterozygosity ( Figure 3B ). Low expression of TP53BP1 was also observed in the post-resistance tumor specimen. Loss of TP53BP1 is expected to facilitate BRCA1-independent end resection following double stranded DNA breaks, since loss of 53BP1 in vitro restores HR in cells lacking BRCA1, leading to PARPi/platinum resistance despite maintained BRCA1 deficiency. 28, 31, 32 Tissue was insufficient for RAD51 staining or 53BP1 protein staining in this patient.
Patient 359, who had a pathogenic germline mutation in BRCA1 and no identified reversion in BRCA1 following exposure to olaparib (Figure 3C) , acquired amplification of MRE11A, which encodes a DNA exonuclease that functions in end resection. 30 MRE11A amplification could plausibly lead to PARPi resistance by increasing end resection at double stranded DNA breaks, therefore restoring HR proficiency in tumor cells despite BRCA1 deficiency. Supporting the functional relevance of the MRE11A amplification in causing resistance to PARP inhibition in this patient, RNA expression of MRE11A was high in the postresistance tumor specimen ( Figure 3D) , and tumor staining for phospho-RPA (a marker of DNA end resection) was substantially increased post-resistance ( Figure 3E-F) . Moreover, RAD51 foci were re-acquired at the post-olaparib timepoint (Figure 3G ), as would be expected for a tumor with HR restoration through increased end resection. In this sample that increased DNA end resection and restored HR without BRCA1 somatic reversion, we propose that the acquisition of MRE11A amplification is the likely biological mechanism of olaparib resistance.
One additional acquired genomic alteration that could potentially contribute to therapeutic resistance was seen in the 20 genes analyzed. Patient 349, with a pathogenic germline mutation in BRCA1 and a putative somatic reversion in BRCA1, acquired biallelic inactivation of KMT2C, a histone methyltransferase necessary for the presence of MRE11 at replication forks, among many other cellular functions. 12, 33 The loss of KMT2C in this patient suggests that a replication fork-stabilizing event may have occurred that subsequently conferred PARPi resistance.
Broader analysis of genomic alterations occurring in a larger set of 276 genes shown to be involved in all DNA damage repair processes in cancer 34 did not reveal any explanatory mechanism of resistance beyond those identified above. In addition, given previous evidence indicating that gene fusions driving overexpression of Abcb1 (drug efflux pump) can cause resistance to PARPi, 10,16 all gene fusion events were examined in the cohort. No fusions in Abcb1 or other genes of interest were identified. Following all analyses, we did not identify any candidate mechanisms in patients 303 or 565, whose acquired resistance remained unexplained.
RAD51 foci and resistance to subsequent lines of platinum chemotherapy or PARPi
Of the six patients who acquired RAD51 foci following exposure to platinum chemotherapy or PARPi, three went on to have subsequent exposure to a different DNAdamaging therapy in a later line of treatment ( Table 2) . In all three cases, patients displayed intrinsic resistance to subsequent PARPi and/or platinum. By contrast, RAD51 foci were absent from all tested tumors prior to initial therapy with PARPi or platinum (Figure 2) , among patients selected for initial response to therapy. The data are consistent with the premise that intact or impaired HR, measured by the presence or absence of RAD51 foci, correlates with response to PARPi/platinum agents in BRCA1/2-deficient tumors, though the number of patients in this cohort is too small to allow definitive conclusions about the clinical utility of RAD51 focus formation as a predictive biomarker.
Discussion
In this study, we used whole exome sequencing of tumor and blood, RNA sequencing of tumor, and formation of RAD51 foci by immunohistochemistry to interrogate resistance to PARP inhibitors or platinum chemotherapy and its correlation with tumor HR proficiency in a cohort of patients with metastatic breast cancer. While the cohort is only eight patients, to our knowledge it is the largest such investigation looking at mechanisms of resistance in BRCA1/2deficient tumor tissue from metastatic breast cancer patients. Reversions were identified in onehalf of patients. Moreover, sequencing data suggest additional, biologically plausible nonreversion mechanisms of resistance as well, including amplification of MRE11A and biallelic inactivation of TP53BP1, each of which may restore HR through increased DNA end resection.
Lastly, the presence or absence of RAD51 foci correlated with resistance or response, respectively, to DNA-damaging therapy, implying that immunohistochemical assessment of RAD51 should be further explored as a clinically deployable predictive biomarker to guide therapeutic decisions in BRCA1/2-deficient tumors.
Reversion to protein-coding BRCA1 or BRCA2 transcript has been previously reported following exposure to platinum chemotherapy and/or PARPi both in preclinical models of BRCA1/2-deficient tumor cells and in patients with BRCA1/2-mutated breast cancer, ovarian cancer, and prostate cancer. 10, 13, 14, 17, 35, 36 The reversions identified in this cohort occurred through a variety of genomic mechanisms, including short deletions nearby to or encompassing a germline frameshift alteration (patient 318), long deletions encompassing a germline frameshift alteration (patients 318, 339, and 349), and deletions or splice site mutations postulated to activate alternative splicing to a functional though possibly hypomorphic BRCA1/2 protein (patients 349 and 510). Prior evidence supports the biological plausibility of each of these revertant mechanisms: BRCA2 proteins with large amounts of protein-coding sequence deleted have been demonstrated following PARPi exposure, and retain HR functionality; 36,37 and activation of alternative splice isoforms has been associated with PARPi or platinum resistance in both BRCA1-and BRCA2-deficient tissue. 26, 35, 38 Our similar observations support the clinical relevance of these events.
It is interesting that despite co-sampling of tissue and ctDNA in 7 of 8 patients, and identification of reversions using both methods, the majority of reversion events were not shared between tumor and blood specimens. The preponderance of events identified in blood only may reflect the fact that multiple post-resistance blood specimens were sequenced in most patients (compared to only a single post-resistance tumor specimen sequenced in all patients). The discordance also highlights the limitations of a single tumor or blood sample in isolation to comprehensively capture heterogeneous genomics across multiple different metastatic lesions at distinct timepoints, and is consistent with a previous report showing incomplete overlap between reversions identified in blood versus tumor. 13 Though genomic reversion is a frequently reported mechanism of clinical resistance to PARPi or platinums among patients with BRCA1/2-mutant tumors, as observed in our cohort, not all patients revert. At present there are no known parameters to predict which patients will acquire somatic reversions and which will not, though this information could carry immense clinical utility as it may identify individuals who would benefit from upfront combined therapeutic strategies to prevent development of resistance. Interestingly, each of the four patients we observed to acquire somatic reversions harbored their original germline mutation within the longest exon of BRCA1/2 transcript (exons 10 and 11 for BRCA1 and BRCA2, respectively). These exons are both above the 99 th percentile for exon length across the human genome), suggesting that perhaps replicative instability of very long exons-particularly with respect to long deletions-could predispose a patient to develop reversions. In addition, a very similar combination of germline mutation and somatic reversion as observed in patient 318 has been previously reported in a patient with ovarian cancer and BRCA2 mutation. 39 Together these observations raise the question of whether the location and/or type of germline mutation in BRCA1/2 may assist in predicting which patients will experience reversion and which will not.
Work to compile and map reversions and associated germline mutations identified to date across tumor types is warranted to address this question.
Non-reversion mechanisms of resistance to PARPi/platinum have been uncommonly identified in clinical specimens; we identified two non-revertant patients in whom genomic evidence supports the acquisition of resistance through upregulation of DNA end resection. Loss of 53BP1, a protein involved in DNA end resection, has been shown to restore HR functionality in BRCA1-deficient cells, and to eliminate the cells' platinum/PARPi sensitivity. 31, 32 Reduced 53BP1 has also been described in platinum and PARPi-resistant ovarian cancer patient tumor specimens and patient-derived xenograft models but to our knowledge has never been demonstrated as a mechanism of resistance in breast tumor specimens. 25, 40, 41 53BP1 normally inhibits the activity of MRE11, a DNA exonuclease, at DNA double stranded breaks. 12 MRE11A amplification (seen here in patient 359 post-olaparib) has not previously been reported as a mechanism of resistance to PARPi/platinum, but is entirely plausible as an alternative means to promote DNA end resection. This biology is supported by increased phospho-RPA staining in our patient's tumor, and represents a potential novel mechanism of resistance identified in this cohort.
It should be noted that MRE11 also plays a role in replication fork degradation, and in this context a theoretical consequence of its amplification could actually be increased sensitivity to PARPi/platinum (i.e. opposite directionality from its effect on double stranded break repair). 12,28 However, the broad evidence supporting 53BP1 loss as a resistance mechanism, the increase in phospho-RPA staining, and the fact that this patient's tumor regained RAD51 foci, all contradict this as a predominant biological effect in this tumor. Conversely, in the case of patient 349 with acquired biallelic inactivation of KMT2C, KMT2C loss could have prevented MRE11 access to replication forks, creating a fork stabilizing event contributing to PARPi resistance. It is noteworthy that this event occurred with a concomitant putative BRCA1 reversion. In ovarian cancer cell line models of PARPi resistance, restoration of HR and stabilization of replication forks have indeed been shown to occur together, 28 suggesting that BRCA1-deficient cells may employ multiple strategies to overcome the pressure of continued PARPi exposure.
Overall, our results are intriguing as they represent the first direct evidence of increased DNA end resection via 53BP1 loss or MRE11 upregulation as a clinically relevant mechanism of resistance to PARPi/platinum in BRCA1-deficient breast tumors. Though numbers are too small to draw any conclusions about the broader prevalence of these mechanisms, it is notable that two of four patients with BRCA1 mutation in our cohort acquire resistance in this manner.
Examination of the DNA end resection pathway-53BP1 and MRE11 in particular-is warranted in larger cohorts of patients with BRCA1 mutation and PARPi/platinum resistance.
Our results suggest that immunohistochemical staining for RAD51 foci offers real-time assessment of a tumor's HR proficiency, and correlates with response and resistance to PARPi/platinum therapy. The feasibility of RAD51 foci staining in human tumors without antecedent exposure to DNA damaging agents has been previously demonstrated in two small cohorts, 25,42 and our results offer further proof-of-concept. The presence of RAD51 foci has been shown to correlate with decreased efficacy of PARP inhibition in patient derived xenografts and in a cohort of 8 patients with germline BRCA1/2 mutation. 25,42 However, we demonstrate here for the first time that the presence or absence of RAD51 staining changes over time as predicted with HR-restoring mechanisms of resistance. Taken together, our data along with previous results strongly suggest that RAD51 staining should be investigated as a predictive biomarker in larger cohorts of BRCA1/2-deficient patients treated with PARPi/platinum.
Our study has several limitations. The cohort size is small, though the availability of paired tumor tissue from 7 of 8 patients offers a unique opportunity to closely examine resistance mechanisms, and to our knowledge this represents the largest such cohort specifically of metastatic breast cancer patients reported to date. As this was not a treatment-based clinical trial, therapies received and biopsy timepoints are heterogeneous, and the biopsies performed do not exactly bracket the PARPi/platinum treatments received. While it is therefore not possible to conclude that the resistance mechanisms identified specifically resulted from selective pressure of PARPi/platinum, each mechanism highlighted has been previously reported to result from PARPi/platinum exposure, or, in the case of MRE11A amplification, is in a known resistance pathway.
In conclusion, we report on a cohort of eight patients with metastatic breast cancer and BRCA1/2-deficient tumors who acquired resistance to PARPi or platinum therapy. Using whole exome and RNA sequencing, with supportive functional evidence from RAD51 foci staining in each case, we identified biologically plausible mechanisms of resistance in 6 patients: four with acquired somatic reversion in BRCA1 or BRCA2, and two with acquired upregulation of DNA end resection. The fact that HR restoration explained resistance in the majority of this cohort suggests that HR-disrupting strategies (such as inhibition of phosphoinositide 3-kinase or cyclindependent kinases), or strategies disrupting both HR and replication fork stability (such as inhibition of ATR or CHK1) 9 may represent the best opportunities to re-sensitize patients to PARPi or platinum therapies. 
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